Kathy Harrison Gaicd work email
- Valid
- Valid
Kathy Harrison Gaicd personal email
Australian biotechnology Company Director and CEO with more than 30 years of experience including in 4 ASX listed biotechnology companies and 9 years of patent attorney practice. Scientist and Patent Attorney by training, Kathy has successfully created value by transitioning biotechnology companies through critical drug development stages. Kathy lead Dimerix Ltd from a private pre-clincial company to an ASX listed company with Phase 2 proof of concept data. Dimerix is now completing a global phase 3 clincial trial. Kathy has subsequently positioned Havah Therapeutics Pty Ltd to access a US based phase 2 trial with the leading breast cancer platform trial consortium (I-SPY), and transitioned the company into a US head quartered entity, positioning it for global growth through access to the deep capital and partnership networks in the USA.Kathy was also selected to participate in the inaugural 2018 SBE Australia Life Sciences Accelerator Program, and is now part of the prestigious US Springboard Alumni Network. Specialties: Accelerating clinical treatment opportunities through critical milestones. Identifying and executing on niche intellectual property opportunities. Building and leading teams. Identification of efficient approaches to drug development opportunities and delivering on project outcomes.
-
Board Member - UsaHavah Therapeutics Jun 2024 - PresentNorth Adelaide, South Australia , Au
-
Ceo (Australia)Havah Therapeutics Nov 2019 - Jun 2024North Adelaide, South Australia , AuHAVAH Therapeutics is a women’s health specialty biopharmaceutical company, focused on developing innovative, proprietary hormonal therapies that aim to help millions of women across the world lead longer, better lives. In 2023, the Havah Therapeutics active agent was included in the most recent clinical trial initiated by the prestigious I-SPY breast cancer clinical trial consortium -RECAST DCIS, bringing new choices to women with DCIS who wish to avoid aggresive surgical treatment options in this non-invasive pre-cancerous condition. The I-SPY series of trials are changing the way new treatments are developed for breast cancer, helping make available new, better and more personalized treatments, faster.In May 2024, Kathy led the execution of a share exchange agreement, resulting in the acquisition of the Australian entity by the newly formed US company - Havah Therapeutics Inc. This acquisition will position Havah to access the deep capital networks and partnership opportunities in the USA for promising prevention and treatment therapies for Breast Cancer.
-
Managing DirectorEstrenue Pty Ltd Nov 2021 - PresentEstrenue is developing a treatment for skin integrity (anti-aging) that delivers generic estradiol to the dermal layers of the skin utilizing a novel non-invasive micro-technology delivery system: Elongated Microparticles (EMP). As Managing Director, Kathy has led the company through 2 seed rounds raising approximately AUD1.4M and overseen development of critical pre clinical data for estradiol and multiple pipeline products, as well as a small proof of concept safety clinical study.See the particles in action at https://youtu.be/Ug4GvNd0j7k -
Life Science Executive Committee MemberSbe Australia Dec 2018 - PresentSydney, Nsw , Au -
AlumnaeSbe Australia Apr 2018 - PresentSydney, Nsw , AuI accelerated my business by completing the 2018 BIOTECH program
-
Head Of Ip StrategyProta Therapeutics Pty Ltd Feb 2019 - Jan 2022Prota Therapeutics is an Australian private company developing immunotherapy based treatments for food allergy. The company’s lead product, based on technology spun out of the Murdoch Children's Research Institute, is under development as a treatment for the most common cause of life-threatening anaphylaxis, peanut allergy.Kathy’s role is to optimise the company’s intellectual property portfolio and strategy to achieve the maximum commercial value for it’s assets.
-
DirectorDisruptive Nutrition Pty Ltd May 2019 - Dec 2020Disruptive Nutrition was a subsidiary of Disruptive Enterprises LLC, focused on advancing disease research and developing formulations as medical foods to potentially benefit patients. Disruptive Nutrition has conducted clinical a safety/tolerability clinical trial in children with Angelman Syndrome at the Vanderbilt Children's hospital.Disruptive Nutrition develops products formulated to not only improve health, but also boost the body’s own ability to combat disease in rare genetic disorders.
-
Chief Operating OfficerDimerix Limited Aug 2018 - Nov 2018Melbourne, Victoria, AuDimerix Limited is an ASX listed Australian Clinical Stage Biotechnology company. Dimerix's lead therapy (DMX-200) is a new therapeutic approach to treating chronic kidney disease. During this period Kathy ensured a seamless transition to the new CEO -
Chief Executive OfficerDimerix Limited Nov 2016 - Aug 2018Melbourne, Victoria, AuAs CEO, Kathy raised $9.5m on the ASX in 13 months on a company capitalised at the time of $10m, and built her team from 1 part time employee to a team of 6 including a Chief Medical Officer and Head of Drug Development.Kathy also delivered positive Phase 2a data in the chronic kidney disease trial, developed an extended release tablet formulation and validated appropriate dosing through a pharmacokinetic study. During 2018 the focus shifted to executing on 2 Phase 2b clinical studies, GMP manufacturing and formulation for an IND, and non clinical studies to progress the program to phase 3 ready for the orphan indication FSGS. Kathy also lead the successful application for orphan drug designation for DMX-200 in Europe.Kathy was selected to participate in the inaugural 2018 SBE Australia Life Sciences Accelerator Program, and is now part of the prestigious US Springboard Alumni Network.Under Kathy's leadership, Dimerix was a 2018 Westpac Business of Tomorrow (200) winner.
-
General ManagerDimerix Limited Mar 2014 - Nov 2016Melbourne, Victoria, AuCommenced as sole full time employee reporting directly to the Board of Directors to take lead clinical pre-clinical asset, DMX-200 into Phase 2 clinical trials, and list company on the ASX. Recruited 27 patients into Phase 2a study, ultimately generating positive safety and indications of efficacy data.Accelerated patent prosecution leading to grant of broad class based method of use patent in the US, and ongoing prosecution in other major jurisdictions.Achieved Orphan Drug designation for DMX-200 and established path to US registration through a pre-IND meeting.
-
Vice President, Ip & Product DevelopmentPhosphagenics Limited Nov 2009 - Feb 2014Clayton, Victoria, AuStrategic creation of intellectual property solutions for a range of commercialisation scenarios. Analysis and preparation of business case for commercial opportunities. Project leader for successful phase II clinical trial for an acne treatment. Implementation of product distribution projects. R&D tax incentive applications and overseas advanced findings. Creating strategic and commercially relevant patent and trade mark properties including management of a growing patent portfolio. Commercially relevant trade mark protection and advice for growing international cosmetic/ personal care business. -
Hr ManagerPhosphagenics Limited Dec 2010 - Sep 2012Clayton, Victoria, AuConsolidation and implementation of HR systems and processes including creation and implementation of annual performance review process and staff HR manual.
-
Head, Intellectual PropertyYm Biosciences Australia (Formerly Cytopia Research Pty Ltd) Dec 2006 - May 2010As secretary of the due diligence committee, pivotal role in the merger of Cytopia into YM Biosciences, which was ultimately sole to Gilead based on the lead clinical asset (momelitinib or CYT387) acquired from Cytopia.Earlier roles at Cytopia included Drafting and prosecution of new patent applications and strategic patent advice; patent portfolio management and IP budget management; license and collaborative research agreement negotiation and management; and International Non Proprietary Name (generic name) development for new pharmaceutical products.
-
Associate Patent AttorneyWatermark Intellectual Property Sep 1997 - Dec 2006Hawthorn, Victoria, AuPatent practice for chemical, biotechnology and pharmaceutical clients. Australian patent and trade mark oppositions. Trade mark searching and advice for a range of clients including in the food, fashion, consumer chemical and electronic device industries. Plant Breeders Rights. -
Technology Transfer CoordinatorAmrad Dec 1992 - Sep 1997Sourcing and evaluating new potential diagnostic and research reagent products.
Kathy Harrison Gaicd Skills
Kathy Harrison Gaicd Education Details
-
Australian Institute Of Company DirectorsGraduate -
Governance Institute Of AustraliaCertificate In Governance Practice
-
The Institute Of Patent And Trade Mark Attorneys Of Australia (Ipta)Diploma In Intellectual Property Practice
-
University Of MelbourneIp Law
-
The University Of ManchesterMolecular Biology
-
Swinburne University Of TechnologyBiochemistry
Frequently Asked Questions about Kathy Harrison Gaicd
What company does Kathy Harrison Gaicd work for?
Kathy Harrison Gaicd works for Havah Therapeutics
What is Kathy Harrison Gaicd's role at the current company?
Kathy Harrison Gaicd's current role is Biotechnology Company Director.
What is Kathy Harrison Gaicd's email address?
Kathy Harrison Gaicd's email address is ka****@****ics.com
What schools did Kathy Harrison Gaicd attend?
Kathy Harrison Gaicd attended Australian Institute Of Company Directors, Governance Institute Of Australia, The Institute Of Patent And Trade Mark Attorneys Of Australia (Ipta), University Of Melbourne, The University Of Manchester, Swinburne University Of Technology.
What skills is Kathy Harrison Gaicd known for?
Kathy Harrison Gaicd has skills like Biotechnology, Intellectual Property, Patents, Technology Transfer, Commercialization, Strategy, Product Development, Patent Prosecution, Due Diligence, Trademarks, Patent Litigation, Patent Applications.
Free Chrome Extension
Find emails, phones & company data instantly
Aero Online
Your AI prospecting assistant
Select data to include:
0 records × $0.02 per record
Download 750 million emails and 100 million phone numbers
Access emails and phone numbers of over 750 million business users. Instantly download verified profiles using 20+ filters, including location, job title, company, function, and industry.
Start your free trial